The specialty-generic drugmaker's EPS rose 13% to 53 cents, beating views by 9 cents. Revenue rose 65% to $66.5 mil, above views. Nearly all its full-year revenue came from Subsys, an under-the-tongue spray version of the painkiller fentanyl, sold in other forms as Actiq and Fentora by Teva Pharmaceutical Industries (TEVA). But this year, Insys Therapeutics (INSY) is launching late-stage clinical trials on 3 other products, which is increasing its R&D spending. Shares rose 0.2% to 55.98.